Itruvone

Itruvone (INNTooltip International Nonproprietary Name; developmental code name PH10), also known as pregn-4-en-20-yn-3-one, is a vomeropherine which is under development by VistaGen Therapeutics as a nasal spray for the treatment of major depressive disorder.[1][2][3][4][5][6]

Itruvone
Clinical data
Other namesPH10; PH10A; PH10 NS; Pregn-4-en-20-yn-3-one
Routes of
administration		Intranasal (spray)
Identifiers
  • (8S,9S,10R,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC21H28O
Molar mass296.454 g·mol−1
3D model (JSmol)
  • C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C#C)CCC4=CC(=O)CC[C@]34C
  • InChI=1S/C21H28O/c1-4-14-6-8-18-17-7-5-15-13-16(22)9-11-21(15,3)19(17)10-12-20(14,18)2/h1,13-14,17-19H,5-12H2,2-3H3/t14-,17-,18-,19-,20+,21-/m0/s1
  • Key:CHOUAXDNNAVGHR-NWSAAYAGSA-N

See also

References
  1. "PH-10 Nasal Spray". AdisInsight. Springer Nature Switzerland AG.
  2. Monti L, Liebowitz MR (February 2022). "Neural circuits of anxiolytic and antidepressant pherine molecules". CNS Spectr. 27 (1): 66–72. doi:10.1017/S109285292000190X. PMID 33092667. S2CID 225053518.
  3. "VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Retrieved 2019-12-19.
  4. "Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more". www.bizjournals.com. San Francisco Business Times. October 29, 2018. Retrieved 20 July 2020.
  5. Liebowitz MR, Nicolini H, Monti L, Hanover R (2013). "PH 10 may be a new rapidly acting intranasally administered antidepressant". American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, FL. {{cite journal}}: Cite journal requires |journal= (help)
  6. Jancin B (2013). "Novel intranasal antidepressant shows results after 1 week". Clinical Psychiatry News. Retrieved 13 January 2016.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.